These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 16251235

  • 21. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
    Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ, Pravastatin in Acute Coronary Treatment (PACT) Investigators.
    Am Heart J; 2004 Jul; 148(1):e2. PubMed ID: 15215811
    [Abstract] [Full Text] [Related]

  • 22. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z, Rahme E, Pilote L.
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [Abstract] [Full Text] [Related]

  • 23. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years.
    Rashidi A, Sehgal AR, Rahman M, O'Connor AS.
    Am J Cardiol; 2008 Dec 15; 102(12):1668-73. PubMed ID: 19064021
    [Abstract] [Full Text] [Related]

  • 24. Frequency of statin use in type 2 diabetics having macrovascular disease- at a Tertiary Care Hospital of Karachi.
    Basit A, Hydrie MZ, Hakeem R, Ahmedani MY, Masood Q.
    J Ayub Med Coll Abbottabad; 2004 Dec 15; 16(4):60-4. PubMed ID: 15762067
    [Abstract] [Full Text] [Related]

  • 25. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
    Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW, REgression GRowth Evaluation Statin Study Group.
    Circulation; 2003 May 20; 107(19):2416-21. PubMed ID: 12742999
    [Abstract] [Full Text] [Related]

  • 26. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D, Collet JP, Cottin Y, Cournot M, Ducimetière P, Ferrières J, Paillard F, Valensi P, Zeller M, Cambou JP.
    Arch Mal Coeur Vaiss; 2007 Jan 20; 100 Spec No 1():57-64. PubMed ID: 17405566
    [Abstract] [Full Text] [Related]

  • 27. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators.
    J Am Coll Cardiol; 2008 Apr 15; 51(15):1448-54. PubMed ID: 18402899
    [Abstract] [Full Text] [Related]

  • 28. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.
    Nefrologia; 2008 Apr 15; 28 Suppl 3():39-48. PubMed ID: 19018737
    [Abstract] [Full Text] [Related]

  • 29. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.
    Zoppini G, Targher G, Chonchol M, Perrone F, Lippi G, Muggeo M.
    Nutr Metab Cardiovasc Dis; 2009 Oct 15; 19(8):580-6. PubMed ID: 19196499
    [Abstract] [Full Text] [Related]

  • 30. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER Study Group.
    Circulation; 2005 Nov 15; 112(20):3058-65. PubMed ID: 16275871
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A, Abad S, Luño J.
    J Am Soc Nephrol; 2006 Dec 15; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Prevalence of kidney insufficiency in primary care population in Spain: EROCAP study].
    de Francisco AL, De la Cruz JJ, Cases A, de la Figuera M, Egocheaga MI, Górriz JI, Llisterri JI, Marín R, Martínez Castelao A.
    Nefrologia; 2007 Dec 15; 27(3):300-12. PubMed ID: 17725449
    [Abstract] [Full Text] [Related]

  • 38. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ, CREDO Investigators.
    Am Heart J; 2008 Apr 15; 155(4):687-93. PubMed ID: 18371477
    [Abstract] [Full Text] [Related]

  • 39. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.
    Baber U, Toto RD, de Lemos JA.
    Am Heart J; 2007 Apr 15; 153(4):471-7. PubMed ID: 17383281
    [Abstract] [Full Text] [Related]

  • 40. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction.
    Lambert ND, Sacrinty MT, Ketch TR, Turner SJ, Santos RM, Daniel KR, Applegate RJ, Kutcher MA, Sane DC.
    Am Heart J; 2009 Apr 15; 157(4):688-94. PubMed ID: 19332197
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.